← Leaderboards
Shylaja Srinivasan
University Of California, San Francisco
$1,337,558
Attributed
$1,337,558
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $340.4K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,337,558 · 2
By mechanism
K23$1,095,308 · 1
R03$242,250 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Christopher Dean Owens$1,282,863
- Jenise C Wong$1,652,628
- Sharad Wadhwani$859,820
- Noah A Zaitlen$7,912,572
- Jennifer K Raymond$1,241,157
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseMetforminKidneyRegimenYouthNon-Insulin-Dependent Diabetes MellitusFundingGeneticEmerging AdultPharmaceutical PreparationsDoseTreatment ResponseAdultAlgorithmsAdolescentDisease ProgressionAdolescenceFutureChildhoodAffectBody SizeDrug DispositionBiostatistical MethodsClinic
Grant awards (7)
Pathophysiological sub-typing of pediatric type 2 diabetes based on clinical and genetic clustering methods$121,125
R03 · FY2025 · DK · contact PI
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes$219,321
K23 · FY2024 · DK · contact PI
Pathophysiological sub-typing of pediatric type 2 diabetes based on clinical and genetic clustering methods$121,125
R03 · FY2024 · DK · contact PI
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes$219,303
K23 · FY2023 · DK · contact PI
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes$219,323
K23 · FY2022 · DK · contact PI
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes$218,036
K23 · FY2021 · DK · contact PI
A comprehensive approach to understanding the determinants of metformin pharmacokinetics and pharmacodynamics in youth with type 2 diabetes$219,325
K23 · FY2020 · DK · contact PI